로딩 중…
지수 로딩 중…
Viking Therapeutics, Inc.
VKTX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$32.61+2.74%
2026-08-03
Financials
Valuation Metrics
Viking Therapeutics, Inc.'s Market Cap is $3.79B. At end of 2025 it was $4.01B. Ranked #1600 of 3,112 in US market (top 51%), #558 of 1,445 on NASDAQ (top 39%), #91 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.79B | US#1,600/3,112 Sec#91/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-535M | US—/3,112 Sec—/269 |
| Total Assets | $522M | US#2,723/3,112 Sec#149/269 |
| Net Assets | $408M | US#2,392/3,112 Sec#130/269 |
| Value | ||
| P/B | 9.27x | US#2,573/3,112 Sec#200/269 |
| FCF Yield | -11.05% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -130.98% | US#2,881/3,112 Sec#229/269 |
| Financial Health | ||
| Debt Ratio | 27.82% | US#300/3,112 Sec#98/269 |
| Total Debt | $4M | US#2,865/3,112 Sec#220/269 |
| FCF | $-418M | US#2,819/3,112 Sec#253/269 |
| Cash | $126M | US#2,062/3,112 Sec#160/269 |
| Current Ratio | 4.72x | US#507/3,112 Sec#152/269 |
| Performance | ||
| 1Y Return | -0.21% | US#2,194/3,112 Sec#202/269 |
| 1M Return | -12.90% | US#2,738/3,112 Sec#191/269 |
| From 52W High | -24.43% | US#1,916/3,112 Sec#134/269 |
| 1Y MDD | -45.14% | US#2,215/3,112 Sec#168/269 |
| Trading | ||
| Volume | 1,544,966 shares | US#1,093/3,112 Sec#100/269 |
| Trading Value | $50M | US#1,361/3,112 Sec#84/269 |
| Per Share | ||
| EPS | $-3.15 | US—/3,112 Sec—/269 |
| BPS | $5.61 | US#2,172/3,112 Sec#122/269 |